City File: Drugs worry
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MEDEVA, the troubled drugs group, will remind shareholders on Tuesday that it is looking for a new chief executive. Bernard Taylor - the former chief executive of Glaxo and no relation to the Martin Taylor who has just joined Barclays - needs to strengthen his board to restore investor confidence.
The half-year profits figure will be meaningless, as it will depend on whether the group has already written off its pounds 10m of extra stocks in its US IMS drug-delivery business. Assuming it has not, pre-tax profits will be about 20 per cent up on last year's pounds 17m. Analysts are predicting a full-year total of pounds 42m. But the market is fearing further bad news and the shares are a gamble at best.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments